Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01069861
Other study ID # A1481276
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date December 2010
Est. completion date November 2011

Study information

Verified date January 2021
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Sildenafil is efficacious in newborns with persistent pulmonary hypertension and its use will reduce the need for inhaled nitric oxide.


Description:

Letter to investigator dated 18 June 2012 that study was to be terminated. Study terminated due to evolved and widespread use of standard of care, relevance of study questioned. No safety reasons or issues.


Recruitment information / eligibility

Status Terminated
Enrollment 4
Est. completion date November 2011
Est. primary completion date November 2011
Accepts healthy volunteers No
Gender All
Age group N/A to 72 Hours
Eligibility Inclusion Criteria: - 72 hours of age; and > or = to 34 weeks gestational age. - Persistent Pulmonary Hypertension of the Newborn or Hypoxic respiratory failure associated with: 1. Idiopathic PPHN or 2. Meconium aspiration syndrome or 3. Sepsis or 4. Pneumonia - Oxygenation Index (OI) >15 and <60 calculated Exclusion Criteria: - Patients already receiving inhaled nitric oxide (iNO) on referral. - Prior or immediate need for full Cardio Pulmonary Resuscitation or Extracorporeal Membrane Oxygenation (ECMO). - Life threatening or lethal congenital anomaly. - Large left to right intracardiac or ductal shunting (diagnosed from echocardiogram on admission to GOSH). - Clinically significant active seizures as per clinical judgment. - Bleeding diathesis as per clinical judgment

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
sildanefil
Intravenous sildenafil citrate will be administered as a loading dose of 0.1 mg/kg given over 30 minutes. This will be followed by a maintenance treatment consisting of an intravenous infusion of 0.03 mg/kg/hr. The duration of the infusion will be determined by the need of the individual patient, but will be reviewed at Day 7 if still ongoing, and will not continue past Day 14.

Locations

Country Name City State
United Kingdom Great Ormond Street Hospital, Paediatric Intensive Care London

Sponsors (1)

Lead Sponsor Collaborator
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Duration of Study Medication The duration of the infusion was determined as per investigator's discretion up to Day 7 or Day 14. Baseline up to Day 14
Primary Percentage of Participants Requiring Inhaled Nitric Oxide (iNO) or Extracorporeal Membrane Oxygenation (ECMO) Percentage of participants who required standard therapy (iNO or ECMO) after failure of study treatment. From start of infusion (baseline) up to Day 14
Primary Number of Participants With Adverse Events (AEs) Based on Severity AE:any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. SAE:AE resulting in any of following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience; persistent/significant disability/incapacity; congenital anomaly. Severity criteria: "mild=does not interfere with participant's usual function; moderate=interferes to some extent with participant's usual function and severe=interferes significantly with participant's usual function". Baseline up to 28 days after last dose
Primary Number of Participants With Abnormal Laboratory Data Criteria for potentially clinically significant (PCS) laboratory values: hematocrit 29.2 percent (%); white blood cell (WBC) count 5.0*10^3, lymphocyte absolute 0.88*10^3, total neutrophils absolute 12.07*10^3, eosinophils absolute 0.50*10^3 per cubic millimeter (/mm^3); calcium 6.8 milligram/deciliter (mg/dL); venous bicarbonate 47.0 milliequivalent/liter (meq/L). Screening, once daily for 3 days, every 48 hours thereafter till the end of infusion (up to Day 14)
Secondary Change From Baseline in Oxygenation Index at Hour 6 and 12 Oxygenation Index (OI) was calculated as the product of fraction of inspired oxygen (FiO2) and Mean Airway Pressure divided by partial pressure of oxygen in arterial blood [(FiO2*Mean Airway Pressure)/PaO2] measured in centimeter of water/millimeter of mercury (cmH2O/mmHg). FiO2 is the measure of oxygen concentration that is breathed. Mean airway pressure is defined as an average of the airway pressure throughout the respiratory cycle. PaO2 is the measure of oxygen level in the arterial blood. Baseline, Hour 6, 12
Secondary Change From Baseline in Differential Saturation (Pre- And Post-ductal) at Hour 6 and 12 Differential oxygenation saturation between preductal and postductal sites as measured by pulse oximetry. A difference of greater than (>) 5 percent (%) to 10% in saturation indicates right-to-left shunt through the ductus arteriosus. Oxygenation saturation is measured as percentage of hemoglobin binding sites occupied by oxygen in the blood. Baseline, Hour 6, 12
Secondary Change From Baseline in Ratio of Partial Pressure of Oxygen in Arterial Blood to the Fraction of Inspired Oxygen (P/F) at Hour 6 and 12 The ratio of partial pressure of arterial oxygen and fraction of inspired oxygen is a comparison between the oxygen level in the arterial blood and the oxygen concentration that is breathed. It helps to determine the degree of any problems with how the lungs transfer oxygen to the blood. Baseline, Hour 6, 12
Secondary Duration of Mechanical Ventilation The number of days from the start to the stop of mechanical ventilation, if multiple ventilations occurred during the follow-up, the sum of the duration of each ventilation was used for analyses. Mechanical ventilation was defined as use of mechanical assistance or replacement of spontaneous breathing. Baseline up to 28 days after last dose
Secondary Time to Receipt of Standard Therapy (Inhaled Nitric Oxide [iNO] or Extracorporeal Membrane Oxygenation [ECMO]) Time from start of treatment up to introduction of standard therapy. If participants did not receive standard therapy within 14 days after initiation of the study treatment, then Day 14 was the censoring time. Baseline up to 28 days after last dose
Secondary Population Pharmacokinetics of Sildenafil Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules. Pre-dose, 5 and 30 minutes post-loading infusion, within 48 to 72, 96 to 120 hours during infusion, within 4 to 8, 18 to 24 and 44 to 48 hours post-maintenance infusion
Secondary Maximum Observed Plasma Concentration (Cmax) of Sildenafil Metabolite (UK-103320) Pre-dose, 5 and 30 minutes post-loading infusion, within 48 to 72, 96 to 120 hours during infusion, within 4 to 8, 18 to 24 and 44 to 48 hours post-maintenance infusion
See also
  Status Clinical Trial Phase
Terminated NCT04344561 - Incline Positioning in COVID-19 Patients for Improvement in Oxygen Saturation N/A
Completed NCT04380727 - Almitrine and COVID-19 Related Hypoxemia
Completed NCT04385823 - Use of High Flow Nasal Cannula Oxygen and Covid-19 Acute Hypoxemic Respiratory Failure
Recruiting NCT04415060 - SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival Phase 3
Withdrawn NCT06043635 - Predictors of Inhaled Nitric Oxide Responsiveness in Patients With PPHN
Terminated NCT04433546 - Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS). Phase 2
Not yet recruiting NCT05689216 - Timed Awake Prone and Repositioning for Patients With Covid-19-induced Hypoxic Respiratory Failure. N/A
Completed NCT02184208 - Retrospective Review of Mechanically Ventilated Patients Using a Continuous Data Collection System. N/A
Completed NCT04648657 - Lung Ultrasound, PEEP and Overdistension (LUPO)
Recruiting NCT06140056 - Two Modes of Mechanical Ventilation for Intensive Care Patients With Low Blood Oxygen Due to Breathing Difficulties N/A
Recruiting NCT03835741 - Automated Adjustment of Oxygen on Patient With Acute COPD Exacerbation - FreeO2 HypHop N/A
Completed NCT03082105 - Snow Physical Properties and Human Ventilatory Response N/A
Recruiting NCT04049240 - Effect of HFNO on Spontaneous Ventilation in Obese Patients During Analgo-sedation for Vitrectomy N/A
Not yet recruiting NCT06336265 - Diaphragmatic Ultrasound to Predict the Therapeutic Effect of High-flow Nasal Cannula Oxygen Therapy